Medtronic Stock News

Buying dividend stocks is always a smart plan. They have historically outperformed non-dividend payers by more than two-to-one (9.2% annualized return compared to 4.3% over the last 50 years, according to data from Hartford Funds and Ned Davis Research).

GALWAY, Ireland , April 24, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has submitted 510(k) applications to the U.S. Food and Drug Administration (FDA) seeking clearance for an interoperable pump. FDA clearance of this pump would pave the way for system integration with a continuous glucose monitoring (CGM) sensor based on Abbott...

FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular risk HRS Satellite Symposium will feature leading experts in electrophysiology, hypertension management and heart failure Presentations will detail clinical results from prior studies demonstrating AVIM therapy's ability to immediately, substantiall...

In recent months, Medtronic has soundly outperformed the S&P 500 index. The company's recent regulatory approvals should bode well for non-GAAP EPS growth in the coming years. Medtronic's interest coverage and net debt to EBITDA ratios are robust.

Investors increasingly seek stable and resilient investments in today's volatile and economically uncertain market. Consequently, it is crucial to identify companies with strong fundamentals, defensive strategies, and dependable shareholder returns.

Medtronic offers a compelling long-term investment opportunity with solid revenue and earnings growth, driven by innovation in the cardiovascular, neuromodulation, and diabetes care segments. Medtronic's 3.4% dividend yield is well-supported by earnings, and management continues to invest in R&D to drive shareholder returns. With a forward P/E of 15.1 versus a historical norm of 18.2, MDT is at...

Latest approval expands Medtronic CGM portfolio in the U.S. GALWAY, Ireland , April 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval for the Simplera Sync™ sensor for use with the MiniMed™ 780G system. With this approval, the MiniMed™ 780G system now offers more flexibility for user...

Dividend stocks are great long-term investments. They've outperformed non-dividend-paying stocks by more than 2-to-1 over the long term.